BioWorld

Sep. 10, 2003

FDA Panel Comes Out In Favor Of Raptiva From Genentech, XOMA

An FDA panel of experts voted in favor of Raptiva, a humanized monoclonal antibody made by Genentech Inc. and XOMA Ltd. for the treatment of moderate to severe plaque psoriasis in adults. (BioWorld Today) Read More

Amgen Files Cinacalcet NDA; Drug Targets Dialysis Patients

Chinese Civet Cats, Dogs, Wild, Tame In Vanguard Of Cracking Nature's SARS Virus Reservoir

Alnylam Signs Deal; Sirna Gets License In Young RNAi Space

Correction

Therion Raises $39M To Expand Operations For Vaccine Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.